Graft-Versus-Host Disease: Symptoms, Prevention, and Treatment After Stem Cell Transplant

Graft-versus-host disease is a possible complication after an allogeneic stem cell transplant, when donor immune cells react against the patient’s tissues. Early recognition, prevention strategies, and coordinated transplant care can help manage symptoms and protect recovery.

Overview

Graft-versus-host disease, often called GVHD, is a condition that may develop after an allogeneic stem cell transplant. In this type of transplant, blood-forming stem cells come from a donor, such as a matched sibling, unrelated donor, or cord blood unit. GVHD occurs when immune cells from the donor recognize the recipient’s body as different and begin to attack healthy tissues.

GVHD is one of the best-known stem cell transplant complications, but it is also closely monitored by transplant teams. It does not happen after an autologous transplant, where a person receives their own stem cells. The condition can range from mild and temporary to more persistent, and outcomes are generally better when symptoms are recognized early and treated in a structured way.

There are two main forms: acute GVHD and chronic GVHD. Acute GVHD usually develops in the first weeks or months after transplant, although timing can vary. Chronic GVHD may appear later and can resemble autoimmune or inflammatory conditions affecting several parts of the body. Some patients have features of both.

Symptoms of GVHD

GVHD symptoms depend on which organs are affected. In acute GVHD, the most common target areas are the skin, digestive tract, and liver. Symptoms may begin subtly, which is why transplant patients are usually asked to monitor daily changes and report concerns promptly.

Possible acute GVHD symptoms include a new rash, redness, itching, or peeling skin; nausea, loss of appetite, abdominal cramping, watery diarrhea, or blood in the stool; and liver-related changes such as yellowing of the skin or eyes, dark urine, or abnormal liver blood tests. Fever, fatigue, and general weakness may also occur, although these symptoms can have many causes after transplant.

Chronic GVHD can affect a wider range of tissues. Patients may notice dry, irritated eyes; dry mouth, mouth ulcers, sensitivity to spicy or acidic foods, or dental problems; skin thickening, tightness, or color changes; joint stiffness or reduced flexibility; persistent cough or shortness of breath; genital discomfort; or changes in liver tests. Because chronic GVHD can develop gradually, regular follow-up visits are important even when recovery seems to be going well.

Causes and Risk Factors

GVHD is caused by a reaction of donor immune cells against the recipient’s tissues. Before transplant, doctors match donors and recipients using human leukocyte antigen, or HLA, markers. A closer HLA match generally lowers the risk, but GVHD can still occur because the immune system recognizes many differences beyond the main matching markers.

Several factors can influence GVHD risk. These include the degree of HLA match, the type of donor, the stem cell source, the conditioning treatment used before transplant, the patient’s age and overall health, and the GVHD prevention regimen. Peripheral blood stem cell grafts may carry a different GVHD risk profile than bone marrow or cord blood grafts. Prior infections and the pace of immune recovery can also affect the post-transplant course.

Importantly, some donor immune activity can be beneficial in certain blood cancers. This is known as the graft-versus-leukemia or graft-versus-tumor effect, where donor immune cells help attack remaining cancer cells. Transplant specialists aim to balance this beneficial effect with prevention and treatment of harmful GVHD.

Diagnosis and Monitoring

Diagnosis begins with a careful review of symptoms, physical examination, and transplant history. Because many post-transplant symptoms can also be caused by infection, medication side effects, nutritional issues, or relapse of the original disease, the transplant team usually evaluates several possibilities at the same time.

Tests may include blood work to check liver function, blood counts, inflammation, infection markers, kidney function, and medication levels. If the skin is involved, a small skin biopsy may help confirm the diagnosis. Digestive symptoms may require stool tests, imaging, or endoscopy with biopsy. Lung symptoms may be evaluated with pulmonary function tests, chest imaging, or bronchoscopy when appropriate.

GVHD is often graded or staged according to organ involvement and severity. This grading helps guide treatment decisions and allows the team to follow whether the condition is improving. Patients are usually advised not to treat new symptoms on their own with over-the-counter medicines, especially anti-diarrheal drugs, herbal products, or skin treatments, unless the transplant team approves them.

Treatment Options

GVHD treatment is individualized. The goal is to calm the donor immune reaction, control symptoms, prevent complications, and preserve the benefits of the transplant. Mild skin-only GVHD may sometimes be treated with topical corticosteroids, moisturizers, and close monitoring. More significant GVHD often requires systemic immunosuppressive medicines.

Corticosteroids are commonly used as initial treatment for moderate or severe GVHD, but they are not the only option. Depending on the case, doctors may use calcineurin inhibitors, mycophenolate, targeted immune therapies, extracorporeal photopheresis, or other medicines recommended in transplant practice. Treatment choices depend on whether GVHD is acute or chronic, which organs are affected, infection risk, previous therapies, and the patient’s overall condition.

Supportive care is a major part of treatment. This may include fluid and nutrition support for digestive GVHD, medicines to protect the stomach, care for mouth pain or dryness, eye drops or ophthalmology care for ocular GVHD, physiotherapy for joint stiffness, and pulmonary care for lung involvement. Because immunosuppression can increase infection risk, preventive antimicrobials, vaccines at the right stage of recovery, and careful monitoring may be recommended.

Patients should take GVHD medicines exactly as prescribed and should not stop them suddenly, even if symptoms improve. Many drugs used after transplant require monitoring for side effects and interactions. Open communication with the transplant team helps adjust treatment safely over time.

Prevention and Self-Care After Transplant

GVHD prevention starts before the transplant with donor selection, HLA matching, and planning of the conditioning regimen. After transplant, most patients receive medicines designed to reduce donor immune overactivity. These may include combinations of immunosuppressive drugs or specific transplant approaches selected by the medical team. Prevention lowers risk but cannot eliminate it completely.

Patients can support recovery by following follow-up schedules, taking medicines on time, and reporting changes early. Skin care is often helpful: gentle cleansing, fragrance-free moisturizers, sun protection, and avoiding harsh products can reduce irritation. Good oral hygiene, regular dental guidance, and attention to dry mouth symptoms are also important, especially in chronic GVHD.

Practical self-care measures include:

• Following food safety advice to reduce infection risk during immune recovery.
• Avoiding tobacco smoke and discussing alcohol use with the transplant team.
• Using sun-protective clothing and sunscreen as advised, because sun exposure may worsen skin GVHD.
• Keeping a symptom diary that records rash, stool frequency, appetite, pain, eye or mouth dryness, breathing changes, and temperature.
• Checking before starting supplements, herbal products, or new medicines, as interactions are common after transplant.

Emotional support is also part of recovery. GVHD can be unpredictable, and patients may feel frustrated by prolonged treatment or changing symptoms. Counseling, family education, rehabilitation, and patient support groups can help patients and caregivers manage the physical and emotional demands of transplant recovery.

When to See a Doctor

After a stem cell transplant, patients should contact their transplant team promptly for any new or worsening symptoms. These include a spreading rash, blistering or peeling skin, persistent diarrhea, abdominal pain, vomiting, blood in the stool, yellowing of the skin or eyes, dark urine, mouth sores that limit eating or drinking, severe eye irritation, unexplained weight loss, cough, shortness of breath, or fever.

Patients should also seek medical advice if they miss doses of immunosuppressive medicines, develop signs of infection, or cannot keep fluids down. Early assessment allows doctors to distinguish GVHD from infections or medication effects and to start the most appropriate care without delay.

Long-term follow-up remains important after the initial transplant recovery period. Chronic GVHD may develop months later, and some symptoms are easier to treat when identified early. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat transplant-related conditions, including GVHD, for international patients who need coordinated evaluation and follow-up.

Frequently asked questions

Is graft-versus-host disease the same as transplant rejection?

No. In organ transplant rejection, the recipient’s immune system attacks the donated organ. In graft-versus-host disease, donor immune cells from the stem cell graft attack the recipient’s tissues. The mechanisms and treatments overlap in some ways but are not the same condition.

Can GVHD happen after any stem cell transplant?

GVHD occurs after an allogeneic stem cell transplant, where the donor is another person. It does not occur after an autologous transplant using the patient’s own cells. The transplant team explains individual risk before the procedure.

What are the earliest signs of GVHD?

Early signs often include a new skin rash, itching, nausea, diarrhea, appetite changes, or abnormal liver blood tests. Some symptoms may be mild at first. Patients should report new changes rather than waiting for them to become severe.

Is GVHD treatable?

Yes, many cases of GVHD can be controlled with timely treatment and careful monitoring. Treatment may include topical therapies, immunosuppressive medicines, supportive care, and organ-specific treatments. The approach depends on severity and the organs involved.

How long does GVHD last?

The duration varies widely. Some acute GVHD improves over weeks with treatment, while chronic GVHD may require longer-term management. Follow-up helps doctors adjust medicines gradually and monitor for side effects.

Can patients prevent GVHD through diet or lifestyle alone?

Diet and lifestyle cannot prevent GVHD by themselves, because it is driven by donor immune cell activity. However, safe nutrition, skin protection, medication adherence, infection prevention, and early symptom reporting can support recovery. Patients should follow the specific plan provided by their transplant team.

References

• European Society for Blood and Marrow Transplantation
• American Society for Transplantation and Cellular Therapy
• National Cancer Institute
• Centers for Disease Control and Prevention
• National Marrow Donor Program

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.